"Peptidyl-Dipeptidase A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, -Xaa-*-Xbb-Xcc, when neither Xaa nor Xbb is Pro. It is a Cl(-)-dependent, zinc glycoprotein that is generally membrane-bound and active at neutral pH. It may also have endopeptidase activity on some substrates. (From Enzyme Nomenclature, 1992)
| Descriptor ID |
D007703
|
| MeSH Number(s) |
D08.811.277.656.350.350.687
|
| Concept/Terms |
Peptidyl-Dipeptidase A- Peptidyl-Dipeptidase A
- Peptidyl Dipeptidase A
- Angiotensin I-Converting Enzyme
- Angiotensin I Converting Enzyme
- Carboxycathepsin
- CD143 Antigens
- Kininase II
- Dipeptidyl Peptidase A
- Antigens, CD143
- Angiotensin Converting Enzyme
- Kininase A
|
Below are MeSH descriptors whose meaning is more general than "Peptidyl-Dipeptidase A".
Below are MeSH descriptors whose meaning is more specific than "Peptidyl-Dipeptidase A".
This graph shows the total number of publications written about "Peptidyl-Dipeptidase A" by people in this website by year, and whether "Peptidyl-Dipeptidase A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1997 | 2 | 0 | 2 |
| 2002 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2020 | 4 | 2 | 6 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Peptidyl-Dipeptidase A" by people in Profiles.
-
Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant. Cells. 2024 Jan 23; 13(3).
-
Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response. Proc Natl Acad Sci U S A. 2023 07 25; 120(30):e2221809120.
-
The SARS-CoV-2 spike S1 protein induces global proteomic changes in ATII-like rat L2 cells that are attenuated by hyaluronan. Am J Physiol Lung Cell Mol Physiol. 2023 04 01; 324(4):L413-L432.
-
Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity. Sci Adv. 2022 10 07; 8(40):eabn3777.
-
Identifying Primate ACE2 Variants That Confer Resistance to SARS-CoV-2. Mol Biol Evol. 2021 06 25; 38(7):2715-2731.
-
Differential expression of ACE2 in the respiratory tracts and its relationship to COVID-19 pathogenesis. EBioMedicine. 2020 10; 60:103004.
-
Immunometabolic Status of COVID-19 Cancer Patients. Physiol Rev. 2020 10 01; 100(4):1839-1850.
-
ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19. J Immunother Cancer. 2020 07; 8(2).
-
A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. Cell Stem Cell. 2020 07 02; 27(1):125-136.e7.
-
Our Response to COVID-19 as Endocrinologists and Diabetologists. J Clin Endocrinol Metab. 2020 05 01; 105(5).